14.25
Schlusskurs vom Vortag:
$14.50
Offen:
$13.715
24-Stunden-Volumen:
1.31M
Relative Volume:
0.77
Marktkapitalisierung:
$780.55M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-2.1991
EPS:
-6.48
Netto-Cashflow:
$-153.08M
1W Leistung:
+2.08%
1M Leistung:
+0.28%
6M Leistung:
-6.80%
1J Leistung:
+86.89%
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
QURE
Uniqure N V
|
14.25 | 764.29M | 15.84M | -308.48M | -153.08M | -6.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
2022-03-17 | Hochstufung | UBS | Neutral → Buy |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-05-21 | Eingeleitet | UBS | Neutral |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
2020-11-11 | Eingeleitet | Berenberg | Buy |
2020-11-09 | Eingeleitet | Jefferies | Buy |
2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2019-12-03 | Eingeleitet | Cowen | Outperform |
2019-12-03 | Eingeleitet | Goldman | Buy |
2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
2019-10-11 | Eingeleitet | Stifel | Buy |
2019-09-25 | Eingeleitet | Bernstein | Outperform |
2019-09-12 | Eingeleitet | Mizuho | Buy |
2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure N.V. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
What drives uniQure N.V. stock priceExceptional trading performance - Autocar Professional
Is uniQure N.V. a good long term investmentHigh-velocity gains - jammulinksnews.com
uniQure N.V. to Report Second Quarter 2025 Financial Results and Host Conference Call on July 29, 2025 - Nasdaq
uniQure to Announce Second Quarter 2025 Financial Results - GlobeNewswire
Gene Therapy Leader uniQure Schedules Q2 2025 Earnings: Key Details for Investors - Stock Titan
What analysts say about uniQure N.V. stockHigh-yield market plays - Autocar Professional
Why uniQure N.V. stock attracts strong analyst attentionReal Chart Play - Newser
What makes uniQure N.V. stock price move sharplyHigh Reward Swing Trades - Newser
(QURE) Trading Advice - news.stocktradersdaily.com
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
(QURE) Technical Data - news.stocktradersdaily.com
uniQure stock rating reiterated at Buy by Stifel ahead of key data - Investing.com
Is uniQure NV overvalued or undervalued? - MarketsMojo
uniQure N.V. director Balachandran Madhavan sells $30,518 in shares - Investing.com
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint - Insider Monkey
11 Best Genomics Stocks to Buy According to Hedge Funds - Insider Monkey
uniQure N.V. chief legal officer Potts sells $70k in shares By Investing.com - Investing.com South Africa
uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha
Assenagon Asset Management S.A. Acquires 261,323 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure shareholders approve executive compensation, board reappointments - Investing.com India
uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa
uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus
RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha
Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World
stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Short Interest Update - Defense World
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):